Biognosys, an expert in next-generation proteomics solutions for drug discovery and development, has announced the operational readiness of its new proteomics facility in Massachusetts.
 
This US expansion facilitates access to select proteomics contract research organization (CRO) services for the company’s US biopharma customers.

About the Facility

The Massachusetts facility will initially focus on TrueDiscovery data-independent acquisition (DIA) discovery proteomics services that offer biopharma researchers high-throughput proteome profiling with industry-leading depth, reproducibility, and cost-efficiency, powered by the Bruker timsTOF mass spectrometry platform. Biognosys also anticipates offering additional discovery and targeted proteomics services for US customers to access domestically in the future.
 
“The opening of our new CRO facility in Massachusetts marks a milestone in our commitment to making proteomics accessible globally for life science research and drug development,” commented Dr. Oliver Rinner, CEO and co-founder of Biognosys. “We are excited to bring our CRO services closer to our US customers and enable them to fully leverage the potential of cutting-edge proteomics for the acceleration of therapeutic discoveries, development and pharmacoproteomics.”
 
In the last 15 years, Biognosys has served US biopharma companies from its facility near Zurich, pioneering the use of next-generation DIA proteomics in drug research. By expanding its presence near the life science cluster in the Boston-Cambridge area, the company plans to extend its collaborations with innovative early and late-stage biotech companies in New England and across the Americas.
 
“Our dual-lab strategy underscores our dedication to providing leading-edge, accessible proteomics solutions,” said Biognosys’ Chief Officer of Scientific Operations (COSO), Dr. Jakob Vowinckel. “The synergy between our Swiss and US facilities allows us to serve diverse customer needs, fostering innovation and collaborations.”
 
To offer customers leading solutions for a wide range of biological applications, Biognosys remains committed to employing mass spectrometry instruments from multiple vendors in its research services.